Use of intravenous isoproterenol for status asthmaticus in children

Area of Science:

• Pediatric Pulmonology
• Critical Care Medicine
• Pharmacology

Background:

• Severe asthma in children (status asthmaticus) can lead to respiratory failure.
• Standard treatments like aminophylline, corticosteroids, and aerosolized medications may be insufficient.
• Intravenous (IV) isoproterenol has been explored for managing severe asthma exacerbations.

Purpose of the Study:

• To evaluate the efficacy and indications of low-dose continuous drip IV isoproterenol in children with severe asthma.
• To determine optimal dosing and administration parameters for IV isoproterenol in this population.

Main Methods:

• Thirty-seven pediatric patients (6 months-16 years) with severe asthma (asthma score ≥6 or PCO2 ≥55 torr) unresponsive to other therapies received IV isoproterenol.
• Initial dose was 0.05 mcg/kg/min, increased incrementally as needed, with continuous IV aminophylline and oxygen.
• Infusion continued until PCO2 ≤40 torr, maintained, then tapered.

Main Results:

• Complete response was observed in 34 patients (89%) with a mean isoproterenol dose of 0.2 mcg/kg/min and mean response time of 1.3 hours.
• One patient had a partial response due to arrhythmia, and another experienced rebound bronchospasm upon abrupt discontinuation.
• The treatment effectively reversed hypercapnia and averted impending respiratory failure.

Conclusions:

• Low-dose IV isoproterenol is an effective treatment for reversing hypercapnia in pediatric status asthmaticus.
• Careful monitoring for limitations and potential complications, such as arrhythmias and rebound bronchospasm, is crucial for safe and effective use.